"We are pleased to engage in this strategic collaboration, bringing together some of the world's strongest physicians and scientists to optimize the development of new therapies for patients with cancer," said Dee Anna Smith, CEO of SCRI. "We look forward to providing AstraZeneca with exceptional drug development services while leveraging an industry-leading opportunity to explore a new way for pharmaceutical drug development companies to collaborate."
"This type of strategic partnership is an exciting opportunity to demonstrate how clinical scientists and industry can collaborate for the greater good of patients. I believe the structure of the relationship will enable us to both adapt and move quickly from one study to the next as the clinical program progresses," said Howard A. "Skip" Burris III, M.D., SCRI chief medical officer and director of drug development.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com
SCRI is a strategic research organization focusing on advancing therapies and accelerating drug development. It is one of the largest clinical research programs in the nation, conducting community-based clinical trials in oncology, car
Copyright©2010 PR Newswire.
All rights reserved